Case Study: Nutritional management of a patient at high risk of developing refeeding syndrome by Dolman, RC et al.
140 2015;28(3)S Afr J Clin Nutr
SASPEN Case Study: Nutritional management of a patient at high risk of developing refeeding syndrome
Dolman RC, PhD, Senior Lecturer; Conradie C, MSc, Lecturer
Lombard MJ, PhD, Senior Lecturer; Nienaber A, MSc, Lecturer; Wicks M, MSc, Lecturer
Centre of Excellence for Nutrition, North-West University, Potchefstroom Campus
Correspondence to: Robin Dolman, e-mail: robin.dolman@nwu.ac.za 
Keywords: refeeding syndrome, nasopharyngeal carcinoma, malnutrition, percutaneous endoscopic gastrostomy
Introduction
Although there are various definitions and diagnoses for refeeding 
syndrome,1,2 it is basically described as the occurrence of a shift in 
fluids and electrolytes when malnourished patients receive artificial 
refeeding (either enteral or parenteral).3 Critically ill patients, such 
as oncology patients and those with chronic malnutrition, are often 
at risk of developing refeeding syndrome, which can be fatal.3 
Psychiatric, physiological, metabolic, surgical and neoplastic-related 
complications also contribute to the risk of the development of 
refeeding syndrome.4  
Glycaemia leads to increased insulin production and decreased 
glycogenolysis during refeeding syndrome. Insulin stimulates 
glycogen, protein and fat synthesis which requires minerals, such as 
phosphate and magnesium, as well as co-factors, such as thiamin.3 
Based on this, those with refeeding syndrome often present with 
salt and water retention, hypokalaemia, hypophosphatemia, rapid 
thiamin depletion and hypomagnesaemia.1
Walmsley grouped patients as either having definite or possible 
refeeding syndrome.1 Patients with definite refeeding syndrome are 
those who present with a fall in serum phosphate levels, as well 
as the accumulation of pathological extracellular fluid. On the other 
hand, possible refeeding syndrome is defined as a fall in either serum 
potassium and/or magnesium, with the accumulation of pathological 
extracellular fluid.1 
It is not possible to accurately report on the incidence and prevalence 
of refeeding syndrome mostly owing to lack of an official definition.1 
Walmsley reviewed studies in which parenteral nutrition was 
examined in the UK and New Zealand, and reported an occurrence of 
refeeding syndrome of approximately 4-5%, based on a very loose 
definition thereof, in patients receiving parenteral nutrition.1 Only 
50% of these cases were identified before the initiation of feeds.1
Very few randomised controlled trials have been conducted for the 
purposes of providing treatment guidance to prevent the development 
of refeeding syndrome.3 However, the National Institute for Health 
and Clinical Excellence (NICE) developed best practice guidelines for 
the identification (Table I), management and evaluation of patients at 
risk of developing refeeding syndrome.5  
To prevent the development of refeeding syndrome, nutrition 
support, either via enteral or parenteral feeding, should be 
cautiously introduced.5 Therefore, feeding should be initiated at 
50% (10 kcal/kg/day) of the initial calculated energy (20 kcal/kg/
day) and protein requirements. This should then be slowly increased 
during the ensuing 24-48 hours, based on individual metabolic and 
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Table I: National Institute for Health and Clinical Excellence criteria for identifying patients at risk of developing refeeding syndrome5
One or more of the following symptoms:
or
Two or more of the following symptoms:
Body mass index < 16 kg/m2 Body mass index < 18.5 kg/m2
Unintentional weight loss greater than 15% in the past 3-6 months Unintentional weight loss greater than 10% in the past 3-6 months
Little or no nutritional intake for more than 10 days Little or no nutritional intake for more than 5 days
Low levels of potassium, phosphate or magnesium before feeding A history of alcohol misuse or drugs, including insulin, chemotherapy, 
antacids or diuretics
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gastrointestinal tolerance. However, full fluid, electrolyte, vitamin and 
mineral requirements should be provided to the patient on the first 
day of feeding.5 
Case study
A 69-year-old woman was admitted to the surgical ward in a 
hospital in North-West province on the first of June 2015 for the 
insertion of a percutaneous endoscopic gastrostomy (PEG) tube, 
after being referred from the oncology department where she was 
admitted two days previously. The patient was newly diagnosed with 
squamous cell carcinoma located behind the nasal cavity, and above 
the border of the soft palate. The carcinoma co-existed with an 
acid-fast Mycobacterium tuberculosis infection, for which she was 
treated. The medical history indicated that she was known to have 
pulmonary tuberculosis, and had already suffered from hearing loss, 
an ototoxic effect of the pulmonary tuberculosis medication, as well 
as blindness due to the carcinoma. She was also known to have 
hypertension, which was controlled with treatment. On admission, 
she presented with symptoms of nasal obstruction, a nodal posterior 
nasopharyngeal mass, cranial nerve palsies, tinnitus, chronic 
headaches and proptosis (the bulging of an eye due to a lesion). 
A detailed diet history could not be obtained, but a family member 
reported an extremely poor dietary intake due to dysphagia of solids 
and fluids in the previous two weeks.
Upon admission to the surgical ward, the patient’s anthropometric 
measurements for height and weight were 1.62 m and 80.9 kg, 
respectively, with a body mass index of 30.8 kg/m2. Her usual body 
weight was approximately 95 kg, with at least 15% unintentional 
weight loss over the previous four months. 
Her urea, electrolyte and phosphate levels were measured daily 
to monitor tolerance of her administered feeds, and to detect the 
development of refeeding syndrome (Table II).  
Discussion 
After an initial assessment, during which the NICE guidelines were 
taken into account, the patient was identified as a patient at high 
risk of developing refeeding syndrome.5 This was based on the 
presence of unintentional weight loss greater than 15% in the past 
four months, little or no nutritional intake during the past 14 days, 
and initial borderline low levels of phosphate and potassium.
Nutritional diagnosis 
The patient presented with a high risk of refeeding syndrome relating 
to minimal nutritional intake for more than 10 days, as evidenced by 
unintentional weight loss (> 15% in four months), and a diet history. 
She also presented with an inability to consume food orally, which 
related to the posterior nasopharyngeal mass, as evidenced by a 
nutritional and clinical assessment. 
The patient further experienced unintentional weight loss, as 
evidenced by anthropometry-related minimal food intake and 
increased requirements due to the carcinoma. 
Based on the nutritional diagnoses, the nutritional goals were 
identified as follow:
• Provide adequate nutrition to meet the patient’s macro- and 
micronutrient requirements, in order to address the malnutrition 
and increased catabolism.
• Correct the patient’s micronutrient deficiencies.
• Adjust the feeding protocol to prevent the development of 
refeeding syndrome.  
Diet prescription
Energy and macronutrient distribution
O’Connor and Nicholls systematically reviewed the available 
research and found that malnutrition was a more important marker 
when identifying patients at risk of refeeding than total energy 
administration on the initiation of feeding.6 Nevertheless, according 
to the available literature, feeding should be initiated at 50% of the 
calculated basal energy expenditure.4 Universally, it is recommended 
that energy requirements be calculated at 10 kcal/kg at the start of 
feeding.4-8 
It is recommended that a more conservative feeding approach 
should be followed with malnourished and critically ill patients (Table 
III). Initially, energy should be restricted to as little as 5 kcal/kg.4,9 
This should slowly be increased in the following seven days to the 
Table II: The patient’s biochemical values on admission and during her stay in the surgical ward
Biochemical parameters Day 1 Day 3 Day 4 Day 5 Day 6 Day 7
Sodium (135.0-147.0 mmol/l) 120.3 130.1 135.5 129.9 131.2 139.1
Potassium (3.3-5.0 mmol/l) 3.2 3.5 3.4 3.8 4.1 4.0
Magnesium (0.6-1.1 mmol/l) 0.58 0.61 0.65 0.68 0.7 0.7
Urea (2.6-7.0 mmol/l) 9.1 7.0 6.4 6.1 5.9 6.0
Creatinine (60.0-120.0 mmol/l) 43.0 40.1 41.2 44.4 45.2 46.9
Phosphate
  (0.8-1.4 mmol/l) 0.79 0.80 0.88 0.85 0.91 0.95
Albumin (35.0-55.0 g/l) 25.0 22.5
C-reactive protein  (< 5.0 mg/l) 120.9 150.9 173.3
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full requirement of 25-35 kcal/kg/day.8 Boateng et al recommend 
a slow energy increase from days 4-10 to reach a total energy 
intake of 15-20 kcal/kg/day.4 The decision to increase or decrease 
energy provision should be based on biochemical and symptomatic 
monitoring.4 
In this case, feeding was initiated at 10 kcal/kg/day and slowly 
increased, as tolerated. The aim was to achieve 20 kcal/kg within 
the first 10 days. After the initial aim of 20 kcal/kg was reached, 
the goal was to further increase intake to 25-35 kcal/kg/day, as 
recommended to patients with head or neck cancer.12 The patient’s 
energy requirements were calculated using actual body weight 
(80 kg).
The calculated macronutrient distribution in the prevention of 
refeeding syndrome, as well as the actual macronutrients delivered 
to the patient, are detailed in Table III. Protein recommendations vary 
between the different literature sources. Stanga et al13 recommends 
that it should comprise 20% of the total energy, and Boateng et al, 
20-30%.4 
It was decided to calculate the protein requirement at 20% of total 
energy for this patient. The goal was to reach a protein intake 
of 1.5 g/kg ideal body weight, as indicated by Viana et al.9 The 
recommended fat and carbohydrate distribution also differs in the 
literature, ranging from 15-40% and 50-60%, respectively. Fat and 
carbohydrates were calculated at 28% and 51% of the total energy, 
respectively, for this patient. 
Practical implementation
As a result of the size and position of the carcinoma, a nasogastric 
tube could not be passed. Furthermore, oral feeding was excluded 
due to dysphagia. As the tumour was inoperable, a long-term feeding 
solution was required. Therefore, a PEG tube was the most practical 
and effective feeding route. A PEG tube was inserted on the second 
day post admission to the surgery ward. Feeding was initiated within 
24 hours post insertion, i.e. on the third day of admission of the 
patient to the surgical ward. 
A semi-elemental feed high in whey peptides, containing fish oil 
and medium-chain triglycerides, was provided in combination with 
an enteral formula that was suitable for the purposes of delivering 
key nutrients, including glutamine, essential for gastrointestinal 
Table III: Macronutrient requirements of patient during the first seven days
Macronutrient requirement Reference Recommendation Actual macronutrient delivered to the patient
Energy NICE5 Initial:10 kcal/kg
Day 4-7: Meets or exceeds requirements
Initial intake: 10 kcal/kg/day
Increased over 3 days to 20 kcal/kg/day
Stanga et al8 Day 1-3: 10 kcal/kg/day
Day 4-6: 15-20 kcal/kg/day
Day 7-10: 20-30 kcal/kg/day
Boateng et al4 Initial: 5 kcal/kg/day
Day 10: Intake of 15-20 kcal/kg
Viana et al9
Stanga et al8 Increase to 25-35 kcal/kg by day 7
Mc Clave et al10 Initiate nutrition support at 25% of the 
estimated goal
Protein Boateng et al4 20-30% of total energy Initial intake: 0.8 g/kg (63 g) (31% total energy) 
Increased to: 1.0 g/kg/day (80.4 g) (20% of total energy)
NICE5 15-20% total energy
Stanga et al8
McClave et al10 Initiate at 25% of actual requirement 
calculated
Crook11 1.2-1.5 g/kg/day
Carbohydrates NICE5 50- 60% total energy Initial intake: 50% of total energy
Increased to: 55% of total energy
Stanga et al8
Crook11 40% of total energy
Fat Boateng et al4 15-40% total energy Initial intake: 19% of total energy




NICE: National Institute for Health and Care Excellence
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resuscitation, i.e. 0.37 g/kg/day glutamine. This combination of 
feeds was given for the first three days post initiation. On the first 
day post the PEG insertion, feeding was started at 40 ml/hour for 24 
hours, and increased in increments of 5 ml/day until 50 ml/hour was 
reached on the third day post feeding initiation. This was decided on 
the basis that biochemical values do not indicate the presence of 
refeeding syndrome. The administration of specialised formula was 
terminated on the fourth day, and the semi-elemental feed continued 
at a rate of 50 ml/hour for 24 hours, as the composition of the feed 
met the nutritional requirements at this rate (20 kcal/hour). The aim 
was to start a polymeric feed on the fifth day (i.e. the seventh day 
post admission of the patient to the surgical ward). However, the 
patient was discharged to the oncology unit before this feed could 
be initiated. 
Micronutrients and refeeding
The provision of phosphorous, potassium, vitamin B complex 
and magnesium were taken into special consideration during the 
development of the nutritional management to prevent refeeding 
syndrome. The clinical consequences of the inadequacy of each 
micronutrient are provided in Table IV, while a summary of the 
treatment options is provided in Table V.
Vitamin B complex
Thiamin deficiency is the most important vitamin to monitor during 
the prevention of refeeding syndrome since it is a co-enzyme in 
carbohydrate metabolism.7 The recommended intake range is 
between 200 and 300 mg daily.5 When repleting thiamin levels, it 
Table IV: Causes of micronutrient inadequacy and the clinical consequences thereof
Micronutrient Causes of micronutrient 
inadequacy
System where the inadequacy 
is presented
Clinical consequences of such inadequacy
Thiamin Increased cellular utilisation Neurological Wernicke-Korsakoff syndrome (an inflammatory, haemorrhagic 
degenerative condition of the brain, in coexistence with amnesia)14
Cardiovascular Congestive heart failure, lactic acidosis and beriberi14
Skeleton Muscle weakness14
Phosphate • Cellular phosphate 
redistribution11
• Poor phosphate intake11




Cardiovascular Arrhythmia, heart failure, cardiomyopathy and shock14
Renal Metabolic acidosis and acute tubular necrosis14
Skeleton Rhabdomyolysis (breakdown of the skeletal muscle fibres), 
weakness, myalgia and diaphragm weakness14
Neurological Delirium, coma, seizures and tetany14
Haematological Haemolysis, thrombocytopenia and leukocyte dysfunction14
Endocrine Hyperglycaemia, insulin resistance and osteomalacia14
Potassium • Redistribution of potassium 
ions11
• Gastrointestinal loss of 
potassium11
• Renal potassium loss11
• Renal tubule mechanisms11
Cardiovascular Hypotension, ventricular arrhythmias, cardiac arrest, bradycardia  
and tachycardia14
Respiratory Hypoventilation, respiratory distress and respiratory failure14
Skeleton Weakness, fatigue and muscle twitching14
Gastrointestinal Diarrhoea, nausea, vomiting, anorexia, paralytic ileus and 
constipation14
Metabolic Metabolic alkalosis14
Magnesium • Cellular magnesium 
redistribution11
• Drug interactions11
• Increased renal loss of 
magnesium11






Cardiovascular Paroxysmal atrial or ventricular arrhythmias14
Respiratory Hypoventilation, respiratory distress and respiratory failure14
Neuromuscular Weakness, fatigue, muscle cramps, ataxia, vertigo, paraesthaesia, 
hallucinations, depression and convulsions14
Gastrointestinal Abdominal pain, diarrhoea, vomiting, loss of appetite, and 
constipation14
Other related consequences Anaemia and hypocalcaemia14
Sodium Serum osmolality changes in the 
central nervous system15
Cardiovascular Heart failure and arrhythmia14
Respiratory Respiratory failure and pulmonary oedema14
Renal Renal failure14
Skeleton Muscle cramps, fatigue, fluid retention and oedema14
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is recommended that an intravenous dose of 300 mg is given when 
the feed is initiated (Table V). A maintenance dose of 100 mg per day 
should then be given.4   
In this case study, thiamin was provided at an initial dose of 
300 mg, followed by a daily maintenance dose of 100 mg. In addition 
to thiamin, vitamin B6 (pyridoxine), vitamin B12 (cobalamin) and the 
patient’s folate levels were also monitored.4  
Phosphorous
Phosphorous is an intracellular mineral which is involved in the 
intracellular processes, together with the structural integrity of the cell 
membranes. It is necessary for the production of energy presented 
in the form of adenosine triphosphate. During the development of 
refeeding syndrome, the depletion of serum phosphorous occurs 
because of the increased phosphorylation of glucose.1 
Hypophosphataemia can be classified into three groups of mild 
(0.75-1.00 mmol/l), moderate (0.50-0.74 mmol/l) and severe 
(< 0.50 mmol/l).4 
Skipper conducted a systematic review of cases with patients 
presenting with refeeding syndrome, and indicated a prevalence of 
hypophosphataemia in up to 96% of patients.2 Thus, it is advisable 
that serum phosphorous levels are closely monitored to prevent the 
development of refeeding syndrome.4 
Phosphate requirements range between 0.3 and 0.6 mmol/kg/
day.4 If mild hypophosphateemia occurs, it should be treated with 
0.32 mmol/kg/day of IV or oral (per os) potassium phosphate, while 
moderate depletion levels should be replaced with 0.64 mmol/kg/
day of IV potassium phosphate (Table V).4 On the other hand, severe 
hypophosphataemia should be treated with 1 mmol/kg/day of IV 
potassium phosphate (Table V).4 However, it is important to continue 
monitoring phosphate levels to prevent neurological symptoms.4 
The patient discussed in this case study had borderline low 
phosphate levels. Her phosphate levels were monitored daily, but the 
levels improved in the days that followed to such an extent that the 
phosphate supplementation was discontinued.  
Potassium
Low potassium levels can lead to hypokalaemia (< 3.5 mmol/l), 
and thus salt and water retention.13 This retention then results in 
oedema, and eventually heart failure.13 It is recommended that 
patients’ potassium levels are monitored daily,4 and if high or low, an 
electrocardiogram should be considered to determine the presence 
of arrhythmia.4 Patients should be provided with 1-4 mEq/kg/day 
of oral potassium in the form of either potassium chloride or other 
potassium formularies (Table V).4 Severe deficiencies should be 
treated with IV supplementation, although this should be monitored 
closely to prevent hyperkalaemia (Table V).4 
In this case study, the patient’s potassium levels were borderline 
low; and although the potassium was not supplemented, it was 
monitored daily.
Table V: A summary of the treatment options for micronutrient inadequacy
Micronutrient Treatment options
Thiamin IV 300 mg when the feed is initiated, and  
100 mg per day as maintenance4
Phosphate
Mild (2.3-3.0 mg/dl) 0.32 mmol/kg*4,16 
Increase dietary intake or oral phosphate 
containing a multivitamin15
Moderate (1.6-0.2 mg/dl) 0.64 mmol/kg4,16 
Oral supplementation: 2.5-3.5 g/day in 
divided doses, or 0.32-0.64 mmol/kg IV  
slowly over 6 hours15
Severe (1.5 mg/dl) 1 mmol/kg*4,16 
1 mmol/kg IV slowly over 8-12 hours15
Potassium
Mild (4.0-3.7 mEq/l) 40 mEq oral or IV16
Increase dietary intake and/or add salt 
substitutes15
Oral supplementation: 40-100 mEq daily in 
divided doses, or 40 mEq IV x 1, or 10 mEq IV 
over 1 hour x 3-4 doses15
Moderate (3.6-3.4 mEq/l) 60 mEq oral or IV16
20 mEq per os every 2 hours x 3 doses, or  
10 mEq IV over 1 hour x 4 doses (recheck and 
repeat, if needed)15
Severe (< 3.3 mEq/l) 80 mEq oral or IV16
40 mEq IV over 2-4 hours (recheck and 
repeat, as needed), or 40 mEq IV over 4 hours, 
as needed15
Magnesium
Mild Oral, increase daily intake, or oral supplement 
(magnesium lactate)15
Moderate 10-15 mmol oral magnesium oxide or citrate4
IV 8-32 mEq (maximum 1.0 mEq/kg) slowly, 
with 8 mEq over 1-2 hours daily15
Severe 25 mmol/day parenteral magnesium4
IV 32-64 mEq (maximum 1.5 mEq) slowly, 




Moderate Consider free water restriction
Provide half normal saline and/or saline 
corrected at a rate of 1-2 mEq/l/hour15
Severe 3% sodium chloride (correct at a rate of  
1-2 mEq/l/hour)15
* Actual body weight (if < 130% of ideal body weight). If > 130% of ideal body weight, then adjust 
body weight, i.e. [ideal body weight + 0.25 (actual body weight − ideal body weight)]16 
IV: intravenous
145 2015;28(3)S Afr J Clin Nutr
SASPEN Case Study: Nutritional management of a patient at high risk of developing refeeding syndrome
Magnesium
Hypomagnesaemia can lead to cardiac arrhythmia, abdominal 
discomfort and/or neuromuscular abnormalities (Table IV).4 Mild to 
moderate hypomagnesaemia (0.5-0.7 mmol/l) should be treated with 
10-15 mmol oral magnesium oxide or citrate (Table V).4 Ideally, when 
severe symptomatic hypomagnesaemia (< 0.5 mmol/l) is present, 
it should be treated with 25 mmol/day parenteral magnesium.4 
However, this should be assessed every 8-12 hours.4
Conclusion
The patient in this case study was transferred to the oncology ward, 
where chemotherapy treatment was planned. Unfortunately, she 
aspirated and passed away owing to complications of aspiration 
pneumonia. The importance of a comprehensive nutritional 
assessment and monitoring are highlighted by this case study. 
Furthermore, as demonstrated by the biochemical profile of this 
case, cautious feeding is essential in the prevention of refeeding 
syndrome in a patient at high risk of developing this syndrome. 
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